GLUCOSE TRANSPORTER TYPE 1 DEFICIENCY SYNDROME (GLUT1) AND USING KETOGENIC DIET IN TREATMENT OF DE VIVO DISEASE (A CASE REPORTS).

Journal Title: World Journal of Pharmaceutical Research - Year 2018, Vol 7, Issue 1

Abstract

We present experience of ketogenic diet (KD) applying in the treatment of pharmacoresistant epilepsy in a patients with glucose transporter deficiency syndrome type I (GLUT1). We observed six children with refractory epilepsy due to GLUT1. The high effectiveness of KD in the treatment of GLUT1 was demonstrated. All patients were achieved complete absence of seizures and EEG abnormalities from the beginning of KD. We noticed positive shift in cognitive and speech development for all children. Antiepileptic drugs were stopped taking due to the stable remission. There was a further positive dynamics in intelligence, psycho-emotional sphere; the children began to go a nursery school and a special school. Thus, the ketogenic diet is high effectiveness and, perhaps, the only method for GLUT1 treatment. For 100% of children with glucose transporter deficiency syndrome type I (GLUT1) using KD to treating and prevention of all types of seizures. The improvement of the quality of life for them we estimated by Hague scale. Using the KD we have achieved the reliable positive changes in the psychomotor development of patients tested by Griffits 2, Griffits 3 scales.

Authors and Affiliations

E. G. Lukyanova

Keywords

Related Articles

REMOVAL OF LEAD AND CADMIUM POLLUTION BY COLUMN TECHNOLOGY USING CERATOPHYLLUM DEMERSUM

Environmental exposure to toxic heavy metals is one of the main critical issues on environmental and public health. Heavy metals are common pollutants in aquatic ecosystems, which are particularly susceptible and often f...

IN VITRO ANTIOXIDANT AND ANTI-INFLAMMATORY PROFILES OF BIOACTIVE FRACTION FROM OPILIA CELTIDIFOLIA (GUILL. & PERR.) ENDL. EX WALP (OPILIACEAE)

Polyphenol contents, antioxidant and anti-inflammatory activities of bioactive fraction (ethyl acetate fraction) of (leaves, leafy stems and roots) from Opilia celtidifolia were investigated in this study in oder to prov...

ROLE OF LAGHUMALINIVASANT RASA IN UPVISHTAK (INTRA UTERINE GROWTH RETARDATION)

Intra uterine growth restriction (IUGR) refers to a condition in which a foetus is unable to achieve its genetically determined potential size. This functional definition seeks to identify a population of foetuses at ris...

CANINE TRANSPOSITIONS –A REVIEW

Tooth transposition is an alteration initially reported in the 19th century[1] and its terminology has been changing. Some publications have classified different degrees of ectopic eruption as pseudo transpositions or in...

SUBSTITUTED BENZIMIDAZOLE A POTENTIAL DRUG CANDIDATE: AN OVERVIEW

Benzimidazole has diverse biological potential and the easy synthetic routes for synthesis have taken attention of the chemists, pharmacologists and researchers. The review of synthetic methods of substituted benzimidazo...

Download PDF file
  • EP ID EP618901
  • DOI -
  • Views 135
  • Downloads 0

How To Cite

E. G. Lukyanova (2018). GLUCOSE TRANSPORTER TYPE 1 DEFICIENCY SYNDROME (GLUT1) AND USING KETOGENIC DIET IN TREATMENT OF DE VIVO DISEASE (A CASE REPORTS).. World Journal of Pharmaceutical Research, 7(1), 311-327. https://europub.co.uk/articles/-A-618901